Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
Despite the significant clinical advances with the Best of bond builders use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients, response rates to the therapy are variable and do not always result in long-term tumor regression.The development of ICI-resistant disease is one of the pressing issue in clinical oncology, and the